Novel Immunotherapy Combos Target TIM-3 and PD-1/PD-L1 Networks
Fred Hirsch, MD, PhD, discusses his research finding the immune checkpoint, TIM-3, shaping up to be a viable target for designing therapies for patients with non–small cell lung cancer and other malignancies.